Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors
L01EM02 Copanlisib
D10867 Copanlisib (USAN/INN)
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Copanlisib
D10867 Copanlisib (USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG03139 PI3K inhibitor
DG01926 Copanlisib
D10867 Copanlisib
Metabolizing enzyme substrate
DG01891 CYP1A1 substrate
DG01926 Copanlisib
D10867 Copanlisib
DG01633 CYP3A/CYP3A4 substrate
DG01926 Copanlisib
D10867 Copanlisib
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Phosphotransferase
PIK3CA
D10867 Copanlisib (USAN/INN)
PIK3CD
D10867 Copanlisib (USAN/INN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10867
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10867
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10867
Drug groups [BR:br08330]
Antineoplastic
DG03139 PI3K inhibitor
DG01926 Copanlisib
Metabolizing enzyme substrate
DG01891 CYP1A1 substrate
DG01926 Copanlisib
DG01633 CYP3A/CYP3A4 substrate
DG01926 Copanlisib